References
Abadie E, Passa PH. Diabetogenic effects of nifedipine. Correspondence. British Medical Journal 289: 438, 1984
Adams PW, Godsland I, Melrose J, et al. The influence of oral contraceptive formulation on carbohydrate and lipid metabolism. Journal of Pharmacotherapy 3: 54, 1980
Adams PW, Oakley NW. Oral contraceptives and carbohydrate metabolism. Clinics in Endocrinology and Metabolism 1: 697–720, 1972
Adnitt PI. Hypoglycaemic action of monoamineoxidase inhibitors (MAOIs). Diabetes 17: 628–633, 1968
Amery A, Berthaux P, Bulpitt C, Deruyttere M, De Schaepdryver A, et al. Glucose intolerance during diuretic therapy: results of trial by the European Working Party on Hypertension in the Elderly. Lancet 1: 681–683, 1978
Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients: a second report from the European Working Party on high blood pressure in the elderly (EWPHE). Postgraduate Medical Journal 62: 919–924, 1986
Amery A, Brixko P, Clement D, De Schaepdryver A, Fagaro R, et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1: 1349–1354, 1985
Ames RP, Hill P. Antihypertensive therapy and the risk of coronary heart disease. Journal of Cardiovascular Pharmacology 4 (Suppl. 2): 206–212, 1982
Andersson DEH, Röjdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin dependent diabetes mellitus. Acta Medica Scandinavica 210: 27–33, 1981
Arneson GA. Phenothiazine derivatives and glucose metabolism. Journal of Neuropsychiatry 5: 181–185, 1964
Ashmore J. The effect of glucocorticoids on insulin action. Diabetes 13: 349–354, 1964
Awoke S, Voyles NR, Bhathena SJ, Tanenberg RJ, Recant L. Alterations of plasma opioid activity in human diabetes. Life Sciences 34: 1999–2006, 1984
Baldwin HS, Dworetsky M, Isaacs NJ. Evaluation of the steroid treatment of asthma since 1950. Journal of Allergy 32: 109–118, 1961
Barnett D, Craig JG, Robinson DS, Rogers MP. Effect of clofibrate on glucose tolerance in maturity onset diabetes. British Journal of Clinical Pharmacology 4: 455–458, 1977
Beable A, Ghurye RS, Micallef-Eynaud P, Baksi AK. Nifedipine and bendrofluazide in the treatment of hypertension in noninsulin-dependent diabetics. Practical Diabetes 6: 233–237, 1989
Beck P, Schalch DS, Parker ML, Kipnis DM, Daughaday WH. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly. Journal of Laboratory Clinical Medicine 66: 366–379, 1965
Belehu A, Naafs B. Diabetes mellitus associated with pentamidine mesylate. Correspondence. Lancet 2: 1463–1464, 1982
Belehu A, Naafs B, Touw-Langendijk E. Failure of metronidazole treatment in Ethiopian mucocutaneous Leishmaniasis. British Journal of Dermatology 99: 421–422, 1978
Benfield GF, Hunter KR. Oxprenolol methyldopa and lipids in diabetes mellitus. British Journal of Clinical Pharmacology 13: 219–222, 1982
Bengtsson C, Blohmé G, Lapidus L, et al. Do antihypertensive drugs precipitate diabetes? British Medical Journal 289: 1495–1497, 1984
Bengtsson C, Blohmé G, Lapidus L, Lundren H. Diabetes in hypertensive women: an effect of antihypertensive drugs on the hypertensive state perhaps. Diabetic Medicine 5: 261–264, 1988
Berglund G, Andersson O. Beta-blockers or diuretics in hypertension? A six-year follow-up of blood pressure and metabolic side effects. Lancet 1: 744–747, 1981
Berglund G, Larsson B, Andersson O, Larsson O, Svärdsudd K, et al. Body composition and glucose metabolism in hypertensive middle-aged males. Acta Medica Scandinavica 200: 163–169, 1976
Bhatnagar SK, Amin MMA, Al-Yusuf AR. Diabetogenic effects of nifedipine. British Medical Journal 289: 19, 1984
Bilo HJH, Westerman RF, Nicolaas-Merkus AM, Donker AJM. Effects of enalapril with and without hydrochlorothiazide in hypertensive patients with non-insulin-dependent diabetes mellitus. Diabetes Research 9: 21–25, 1988
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. British Medical Journal 293: 471–474, 1986
Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. American Journal of Medicine 83: 26–36, 1987
Blazar BR, Whitley CB, Kitabchi AE, Tsai MY, Santiago J, et al. In vivo chloroquine induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 33: 1133–1137, 1984
Bloomgarden ZT, Ginsberg-Fellner F, Fayfield EJ, Bookman J, Brown WV. Elevated haemoglobin A1C and low density lipoprotein cholesterol levels in thiazide treated diabetic patients. American Journal of Medicine 77: 823–827, 1984
Bouchard P, Sai P, Reach G, Caubarrère I, Ganeval D. Diabetes mellitus following pentamidine-induced hypoglycaemia in humans. Diabetes 31: 40–45, 1982
Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, et al. Factors associated with early remission of Type I diabetes in children treated with cyclosporine. New England Journal of Medicine 318: 663–670, 1988
Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin dependent diabetic man. Diabetologia 28: 671–676, 1985
Breckenridge A, Welborn TA, Dollery CT, Fraser F. Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet 1: 61–64, 1967
Broadstone VL, Pfeifer MA, Bajaj V, Stagner JI, Samols E. α-Adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes 36: 932–937, 1987
Bruni JF, Watkins WB, Yen SSC. Beta-endorphin in the human pancreas. Journal of Clinical Endocrinology and Metabolism 49: 649–651, 1979
Bryceson ADM. Pentamidine induced diabetes mellitus. East African Medical Journal 45: 110–117, 1968
Buchler D, Warren JC. Effects of estrogen on glucose tolerance. American Journal of Obstetrics and Gynaecology 95: 479–483, 1966
Butler WJ, Ostrander Jr LD, Carman WJ, Lamphiear DE. Diabetes mellitus in Tecumseh, Michigan: prevalence, incidence and associated conditions. American Journal of Epidemiology 116: 971–980, 1982
Byam N, Patrick AL. Efficacy and safety of medium term indapamide treatment in hypertensive diabetic patients. West Indian Medical Journal 34: 261–264, 1985
Cantarovich D, Murat A, Hourmant M, Bardet S, Soulillou JP. Is cyclosporine toxic for human pancreas? Transplantation Proceedings XX (Suppl. 3): 449–452, 1988
Caprio S, Ray TK, Boden G, Reichard Jr GA, Shuman CR, et al. Improvement of metabolic control in diabetic patients during mebendazole administration: preliminary studies. Diabetologia 27: 52–55, 1984
Caro JF, Muller G, Glennon JA. Insulin processing by the liver. Journal of Biological Chemistry 257: 8459–8466, 1982
Caruso M, Orszulak TA, Miles JM. Lactic acidosis and insulin resistance associated with epinephrine in a patient with noninsulin-dependent diabetes mellitus. Archives of Internal Medicine 147: 1422–1424, 1987
Castrignano R, D’Angelo A, Pati T, Al Awady M, Tronca R, et al. A single-blind study of doxazosin in the treatment of mildto-moderate essential hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. American Heart Journal 116: 1778–1784, 1988
Ceriello A, Giugliano D, Dello Russo P, Sgambato S, D’Onofrio F. Increased glycosylated haemoglobin A1 in opiate addicts: evidence for hyperglycemic effect of morphine. Correspondence. Diabetologia 22: 379, 1982
Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 28: 189–235, 1984
Change KJ, Cuatrecasas P. Heterogeneity and properties of opiate receptors. Federation Proceedings 40: 2729–2734, 1981
Chapman MG. Salbutamol induced acidosis in pregnant diabetics. British Medical Journal 1: 639–640, 1977
Charles S, Keterslegers JM, Buyschaert M, Lambert AE. Hyperglycaemic effect of nifedipine. British Medical Journal 283: 19–20, 1981
Clissold SP, Brogden RN. Piretanide: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 29: 489–530, 1985
Collins WCJ, Cullen MJ, Feely J. Calcium channel blocker drugs and diabetic control. Clinical Pharmacology and Therapeutics 42: 420–423, 1987
Colwell JA. Inhibition of insulin secretion by catecholamines in pheochromocytoma. Annals of Internal Medicine 71: 251–256, 1969
Conn J, Fajans S. Influence of adrenal cortical steroids on carbohydrate metabolism. Metabolism 5: 114–127, 1956
Connacher AA, Eidenbani AH, Isles TE, Stevenson IH. Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine. European Journal of Clinical Pharmacology 33: 81–83, 1987
Connor H, Marks V. Alcohol and diabetes. Diabetic Medicine 2: 413–416, 1985
Conrad KA, Fagan TC, Lee SM, Simons JA. Effect of tripamide on glucose tolerance in patients with hypertension. Clinical Pharmacology and Therapeutics 40: 476–479, 1986
Crane MG, Harris JJ. Effect of spironolactone in hypertensive patients. American Journal of Medical Science 260: 311–330, 1970
Crosley Jr JP, Ronquillo LM, Strickland WH, Alexander F. Triamterene, a new natriuretic agent: preliminary observations in man. Annals of Internal Medicine 56: 241–251, 1962
Cruz-Vidal M, Costas Jr R, Garcia-Palmieri MR, Sorlie PD, Hertzmark E. Factors related to diabetes mellitus in Puerto Rican men. Diabetes 28: 300–307, 1979
Cudworth AG, Cunningham JL. The effect of diphenylhydantoin on insulin response. Clinical Science and Molecular Medicine 46: 131–136, 1974
Dargie HJ, Dollery CT. Adverse reactions to diuretic drugs. In Dukes MNG (Ed.) Meyler’s side effects of drugs, Vol. 8, pp. 491, Excerpta Medica, Amsterdam, 1975
Davidson MB. The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism 28(6): 688–705, 1979
De Fronzo RA, Ferrannini E, Koivisto V. New concepts in the pathogenesis and treatment of non-insulin-dependent diabetes mellitus. American Journal of Medicine 74 (Suppl. 1): 52–80, 1983
Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, et al. Sodium restriction and blood pressure in hypertensive Type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. British Medical Journal 298: 227–230, 1989
Dollery CT, Pentecost BL, Samaan NA. Drug-induced diabetes. Lancet 2: 735–737, 1962
Dominguez JR, de la Calle H, Hurtado A, Robles RG, SanchoRof J. Effect of converting enzyme inhibition in hypertensive patients with non-insulin-dependent diabetes mellitus. Postgraduate Medical Journal 62 (Suppl. 1): 66–68, 1986
Donnelly T, Harrower ADB. Effect of nifedipine on glucose tolerance and insulin secretion in diabetic and non-diabetic patients. Current Medical Research Opinion 6: 690–693, 1980
Dornhorst A, Ouyang A. Effect of alcohol on glucose tolerance. Lancet 2: 957–959, 1971
Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in Type II diabetes without alteration of insulin secretion. Lancet 1: 123–126, 1985
Dukes MNG (Ed.). Meyler’s side effects of drugs, 10th ed., Elsevier, Amsterdam, New York, 1984
Dunn JP, Ipsen J, Elsom KO, Ohtani M. Risk factors in coronary artery disease, hypertension and diabetes. American Journal of Medical Science 259: 309–322, 1970
Epstein FH, Ostrander LD, Johnson BC, Payne MW, Hayner NS, et al. Epidemiological studies of cardiovascular disease in a total community: Tecumseh, Michigan. Annals of Internal Medicine 62: 1170–1187, 1965
Exton JH, Mallette LE, Jefferson LS, Wong EHA, Friedmann N, et al. The hormonal control of hepatic gluconeogenesis. Recent Progress in Hormone Research 26: 411–461, 1970
Fariss B, Lutcher CL. Diphenylhydantoin-induced hyperglycaemia and impaired insulin release. Diabetes 20: 177–181, 1971
Feldberg WS, Smyth DG. C-fragment of lipotropin: an endogenous potent analgesic peptide. British Journal of Pharmacology 60: 445–453, 1977
Feldman JM, Boyd AE, Lebovitz HE. Structural determinants of catecholamine action on in vitro insulin release. Journal of Pharmacology and Experimental Therapeutics 176: 611–621, 1971
Felig PL. Glucagon: physiologic and diabetogenic role. New England Journal of Medicine 283: 149–150, 1970
Fenderson RW, Deutsch S, Menachemi E, Chin B, Samuel P. Effect of gemfibrozil on serum lipids in man. Angiology 33: 581–593, 1982
Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, et al. Insulin resistance in essential hypertension. New England Journal of Medicine 317: 350–357, 1987
Ferrari C, Frezzati S, Romussi M, Bertazzoni A, Testori GP, et al. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridaemia. Metabolism 26: 129–139, 1977
Fernere M, Lachkar H, Rochard J-L, Bringer J, Orsetti A, et al. Captopril and insulin sensitivity. Correspondence. Annals of Internal Medicine 102: 134–135, 1985
Field JB. Extraction of insulin by liver. Annual Review of Medicine 24: 309–314, 1973
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. New England Journal of Medicine 317: 1237–1245, 1987
Friedenberg R, Metz R, Mako M, Surmaczynska B. Differential plasma insulin response to glucose and glucagon stimulation following ethanol priming. Diabetes 20: 397–403, 1971
Fulcher GR, Jones IR, Alberti KGMM. Improvement in glucose tolerance by reduction of lipid concentrations in non-insulindependent diabetes mellitus. Diabetes News IX: 4–6, 1988
Fuller JH, McCartney P, Jarrett RJ, Keen H, Rose G, et al. Hyperglycaemia and coronary heart disease: the Whitehall Study. Journal of Chronic Diseases 32: 721–728, 1979
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 2: 1373–1376, 1980
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. British Medical Journal 287: 867–870, 1983
Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. New England Journal of Medicine 318: 81–86, 1988
Garrett BN, Raskin P, Kaplan NM. Metoprolol in diabetes mellitus: effect on glucose homeostasis. Clinical Science 59(Suppl. 6): 469–472, 1980
Gill JS, Al-Hussary N, Atkins TW, Taylor KG, Beevers DG. Possible role for insulin receptors in the mechanism of thiazide induced glucose tolerance. Journal of Hypertension 2 (Suppl. 3): 573–576, 1984
Giugliano D, Ceriello A, Di Pinto P, Saccomanno F, Gentile S, et al. Impaired insulin secretion in human diabetes mellitus: the effect of naloxone-induced opiate receptor blockade. Diabetes 31: 367–370, 1982
Giugliano D, Quatraro A, Ceriello A, D’Onofrio F. Endogenous opiates, heroin addiction, and noninsulin-dependent diabetes. Lancet 2: 769–770, 1985
Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, et al. Impairment of insulin secretion in man by nifedipine. European Journal of Clinical Pharmacology 18: 395–398, 1980
Giugliano D, Torella R, Sgambato S, D’Onofrio F. Acetylsalicylic acid restores acute insulin response reduced by frusemide in man. Diabetes 28: 841–845, 1979
Goa KL, Campoli-Richards DM. Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs 33: 242–258, 1987
Goldberg EM, Sanbar SS. Hyperglycaemic, non-ketotic coma following administration of Dilantin (diphenylhydantoin). Diabetes 18: 101–106, 1969
Goldner MG, Zanowitz H, Akgour S. Hyperglycaemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New England Journal of Medicine 262: 403–405, 1960
Greenblatt DJ, Duhme DW, Allen MD, Koch-Weser J. Clinical toxicity of frusemide in hospitalised patients: a report from the Boston Collaborative Drug Surveillance Program. American Heart Journal 94: 6–13, 1977
Greenwood RH, Luzio SD, Gibby O, Mahler RF, Hales CN. The pharmacological modification of insulin secretion. In Waldhausl WK (Ed.) Proceedings of the 10th Congress of the IDF, Vienna, Austria, International Congress Series No. 500, pp. 566–570, Excerpta Medica, Amsterdam, 1979
Grodsky GM, Bennett LL. Cation reqúirements for insulin secretion in the isolated perfused pancreas. Diabetes 15: 910–912, 1966
Gündo~gdu AS, Brown PM, Juul S, Sachs L, Sönksen PH. Comparison of hormonal and metabolic effects of salbutamol infusion in normal subjects and insulin-requiring diabetics. Lancet 2: 1317–1321, 1979
Guthrie GP. Low dose oral and transdermal therapy of hypertension. In Weber MA et al. (Eds) Diabetes and hypertension, pp. 39–43, Springer-Verlag, New York, 1985
Halter JB, Graf RJ, Porte Jr D. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. Journal of Clinical Endocrinology and Metabolism 48: 946–954, 1979
Hamman RF, Bennett PH, Miller M. Incidence of diabetes among the Pima Indians. In Levine R & Lust R (Eds) Advances in metabolic disorders, Vol. 9, pp. 49–63, Academic Press, New York, 1978
Harrower ADB, McFarlane G. Antihypertensive therapy in diabetic patients: the use of indapamide. American Journal of Medicine 84 (Suppl. 1B): 89–91, 1988
Harrower ADB, McFarlane G, Donnelly T, Gray CE. Blood pressure and diabetic control: results of indapamide treatment. Practitioner 228: 602–603, 1984
Hauger-Klevene JH, Scornavacchi JC. The improvements of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year. European Journal of Clinical Pharmacology 29: 391–393, 1985
Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 32: 106–111, 1983
Helgeland A, Hagelund CH, Strammen R, Tretli S. Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. Lancet 1: 872–875, 1986
Hellman B. The significance of calcium for glucose stimulation of insulin release. Endocrinology 97: 392–398, 1975
Heninger GR, Mueller PS. Carbohydrate metabolism in mania. Archives of General Psychiatry 23: 310–319, 1970
Henquin JC, Charles S, Henquin M, Mathot F, Tamagawa T. Diazoxide and D600 inhibition of insulin release. Diabetes 31: 776–783, 1982
Henwood JM, Heel RC. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36: 429–454, 1988
Henwood JM, Todd PA. Ibopamine: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 36: 11–31, 1988
Herriott SC, Percy-Robb IW, Strong JA, Thomson CG. The effect of Atromid on serum cholesterol and glucose tolerance in diabetes mellitus. Journal of Atherosclerotic Research 3: 679–688, 1963
Hicks BH, Ward JD, Jarrett RJ, Keen H, Wise P. A controlled study of clopamide, clorexolone and hydrochlorothiazide in diabetics. Metabolism 22: 101–109, 1973
Hiles BW. Hyperglycemia and glycosuria following chlorpromazine therapy. Correspondence. Journal of the American Medical Association 162: 1651, 1956
Hopper AH, Tindall H, Davies JA. Effect of aspirin on glucose tolerance and insulin levels in patients with Type 2 diabetes mellitus. Correspondence. Thrombosis and Haemostasis 54: 895, 1985
Hosker JP, Burnett MA, Davies EG, Matthews DR, Rudenski A, et al. Loss of normal sigmoid dose-response curve to glucose in non-insulin dependent diabetes. Abstract no. 232. Diabetologia 27: 289A, 1984
Houston MC. Clonidine hydrochloride. Southern Medical Journal 75: 713–721, 1982
Hutchinson JG. The hypotensive action of ethacrynic acid. Vascular Diseases 5: 104–117, 1968
Illingworth DR. Lipid-lowering drugs. Drugs 33: 259–279, 1987
Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria and haemoglobin A1 in noninsulin-dependent diabetics. Journal of Cardiovascular Pharmacology 8 (Suppl. 11): 96–99, 1986
Jarrett RJ. Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg or neither? Diabetologia 26: 99–102, 1984
Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten-year mortality rates in newly diagnosed diabetes, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 22: 79–84, 1982
Jarrett RJ, Shipley MJ. Mortality and associated risk factors in diabetes. Acta Endocrinologica 110 (Suppl. 272): 21–26, 1985
Jarrett RJ, Stern MP. Non-insulin dependent diabetes. The 2nd Juvenile Diabetes Foundation International World Conference on Diabetes Research. New Frontiers, pp. 45–47, Juvenile Diabetic Foundation, 1988
Jauch K-W, Hartl W, Guenther B, Wicklmayr M, Rett K, et al. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation 17: 448–454, 1987
Javier Z, Gershberg H, Hulse M. Ovulatory suppressants, estrogens and carbohydrate metabolism. Metabolism 17: 443–456, 1968
Jeanrenaud X, Maeder E, Del Pozo E, Felber JP. Effect of an enkephalin-analogue (FK 33-824) on glucose tolerance in man. Acta Endocrinologica 104: 85–90, 1983
Jones GR, Lazarus JH, Davies CJ, Greenwood RH. The effect of short term lithium carbonate in Type II diabetes mellitus. Hormone Metabolic Research 15: 422–424, 1983
Joplin GF, Fraser R, Keeley KJ. Prednisone-glycosuria test for prediabetes. Lancet 2: 67–70, 1961
Jung CY, Mookerjee BK. Inhibitory effect of frusemide on glucose transport. Journal of Laboratory Clinical Medicine 87: 960–966, 1976
Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26: 44–49, 1984
Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2: 120–126, 1979
Kaplan JM, Mass JW, Pixley JM, Ross WD. Use of imipramine in diabetics. Journal of the American Medical Association 174: 511–517, 1960
Keen H, Jarrett RJ, McCartney M. The ten-year follow-up of the Bedford Survey (1962–1972): glucose tolerance and diabetes. Diabetologia 22: 73–78, 1982
Keeney EL. The condition of asthmatic patients after daily longterm corticosteroid treatment. Arizona Medicine 21: 463–469, 1964
Kessler I. Mortality experience of diabetic patients. American Journal of Medicine 51: 715–724, 1971
King H, Zimmet P, Raper LR, Balkau B. The natural history of impaired glucose tolerance in the micronesian population of Nauru: a six-year follow-up study. Diabetologia 26: 39–43, 1984
Kizer JS, Vargas-Cordon M, Brendel K, Bressler R. The in-vitro inhibition of insulin secretion by diphenylhydantoin. Journal of Clinical Investigation 49: 1942–1948, 1970
Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thrombosis and Haemostasis 51: 157–164, 1984
Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. Journal of Clinical Investigation 68: 957–969, 1981
Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K. The effect of gemfibrozil on serum lipids in diabetic patients. Annals of Clinical Research 11: 240–245, 1979
Korhonen T, Uusitupa M, Voutilainen E, Sarlund H, Laakso M, et al. Lack of effect of hepatic enzyme induction on metabolic control in patients with Type 2 (non-insulin-dependent) diabetes. Clinical Pharmacology and Therapeutics 41: 633–638, 1987
Kotier MN, Berman L, Rubenstein AH. Hypoglycaemia precipitated by propranolol. Lancet 2: 1389–1390, 1966
Krolewski AS, Czyzyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics. Diabetologia 13: 345–350, 1977
Lahtela JT, Gachalyi B, Eksymä S, Hämäläinen A, Sotainiemi EA. The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. British Journal of Clinical Pharmacology 21: 19–26, 1986
Lahtela JT, Sarkka P, Sotaniemi EA. Phenobarbital treatment enhances insulin mediated glucose metabolism in man. Research Communications in Chemical Pathology and Pharmacology 44: 215–226, 1984
Lancaster SG, Sorkin EM. Bisoprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 36: 256–285, 1988
Leary WP, Reyes AJ. Piretanide in the treatment of hypertension: effects on arterial blood pressure and several blood variables. South African Medical Journal 60: 925–928, 1981
Leblanc H, Lachelin GCL, Abu-Fadil S, Yen SSC. The effect of dopamine infusions on insulin and glucagon secretion in man. Journal of Clinical Endocrinology and Metabolism 44: 196–198, 1977
Lederle RM. Captopril and hydrochlorothiazide in the fixed combination multicenter trial. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): 63–69, 1985
Leslie RDG, Coats PM. Salbutamol-induced diabetic ketoacidosis. Correspondence. British Medical Journal 2: 768, 1977
Levin SR, Booker J, Smith DF, Grodsky GM. Inhibition of insulin secretion in vitro by diphenylhydantoin. Journal of Clinical Endocrinology and Metabolism 3: 400–401, 1970
Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1: 564–566, 1976
Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. Journal of Allergy and Clinical Immunology 49: 329–336, 1972
Limone P, Cagliero E, Massara F, Molinatti GM. Reduced glucose tolerance after guanfacine in normal and obese patients. Hormone and Metabolic Research 15: 352, 1983
Long CNH, Katzin B, Fry EG. The adrenal cortex and carbohydrate metabolism. Endocrinology 26: 309–344, 1940
Lorenzi M, Tsalikian E, Bohannon NV, Gerich JE, Karam JH, et al. Differential effects of L-dopa and apomorphine secretion in man: evidence against central dopaminergic stimulation of glucagon. Journal of Clinical Endocrinology and Metabolism 45: 1154–1158, 1977
Lundgren H, Björkman L, Keiding P, Lundmark S, Bengtsson C. Diabetes in patients with hypertension receiving pharmacological treatment. British Medical Journal 297: 1512, 1988
Mannisto PT. Endocrine side effects of lithium. In Johnson FN (Ed.) Handbook of lithium therapy, pp. 310–322, MTP Press Ltd, Lancaster, 1980
Marble A, Weir GC, Selenkow HA, Rose LI, Dluhy RC, et al. Endocrine diseases. In Speight TM (Ed.) Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics, 3rd ed., pp. 540–543, ADIS Press Ltd, Auckland, 1987
Marks J, Howard AN. A comparative study of gemfibrozil and clofibrate in the treatment of hyperlipidaemia in patients with maturity-onset diabetes. Research and Clinical Forums 4: 95–103, 1982
Marre M, Chatellier G, Leblanc H, Guyenne TT, Menard J, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. British Medical Journal 297: 1092–1095, 1988
Matthews DM, Wathen CG, Bell D, Collier A, Muir AL, et al. The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics. Postgraduate Medical Journal 62 (Suppl. 1): 73–75, 1986
McMonagle J, Felig P. Effects of ethanol ingestion on glucose tolerance and insulin secretion in normal and diabetic subjects. Metabolism 24: 625–632, 1975
McMurray J, Fraser DM. Captopril, enalapril and blood glucose. Correspondence. Lancet 1: 1035, 1986
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97–104, 1985
Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539–542, 1981
Metz SA, Halter JB, Robertson RP. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Diabetes 27: 554–562, 1978
Micossi P, Pollavini G, Raggi U, Librents MC, Garimberti B, et al. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Hormone and Metabolic Research 16: 59–63, 1984
Mignano C, Berri F, Carta G, et al. Endorphins: a cause of noninsulin-dependent diabetes? In Belfiore F et al. (Eds) Diabetes mellitus: etiopathogenetic and metabolic aspects, pp. 212–214, Karger, Basel, 1984
Miller RD. Atromid in the treatment of post-climacteric diabetes. Journal of Atherosclerotic Research 3: 694–700, 1963
Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. British Medical Journal 285: 685–688, 1982
Monier H, Bravo EL, Tarazi RC. Glucose intolerance during chronic β-adrenergic blockade in man. Abstract. Clinical Pharmacology and Therapeutics 25: 237, 1979
Moore MP, Elliott TW, Nicholls MG. Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. Diabetes Care 11: 397–401, 1988
Mueller-Oerlinghausen VB, Passoth PM, Poser W, Schleckt W. The influence of long-term treatment with major tranquillizers or lithium salts on the carbohydrate metabolism. Arzneimittel-Forschung/Drug Research 28: 1522–1524, 1978
Muggeo M, Acipimox Co-operative Italian Group, University of Verona. Long-term multicentre trial with acipimox in diabetic patients with hyperlipoproteinaemia. Proceedings of the 6th International Meeting on Atherosclerosis and Cardiovascular Diseases, Bologna, October, 1986
Multicentre Study Group. Multicentre comparison of amiloride, hydrochlorothiazide and hydrochlorothiazide plus amiloride in essential hypertension. Archives of Internal Medicine 141: 482–486, 1981
Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet 2: 1293–1295, 1982
Neaton JD, Keller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration and diastolic blood pressure among black and white males followed up for 5 years. American Heart Journal 108: 759–769, 1984
Newman WP, Brodows RG. Aspirin causes tissue insensitivity to insulin in normal man. Journal of Clinical Endocrinology and Metabolism 57: 1102–1106, 1983
Odigwe CO, McCulloch DO, Tunbridge WMG. A trial of the calcium antagonist nisoldipine in hypertensive non-insulin dependent diabetic patients. Diabetic Medicine 3: 463–467, 1986
O’Hare JA. The enigma of insulin resistance and hypertension, insulin resistance, blood pressure and the circulation. American Journal of Medicine 84: 505–509, 1988
Ohlson LO, Bjuro T, Larsson B, Eriksson H, Svardsudd K, et al. A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67 year old men. Diabetic Medicine 6: 112–120, 1989
Okada S, Miyi Y, Sato K, Masaki Y, Higuchi T, et al. Effect of clonidine on insulin secretion: a case report. Journal of International Medical Research 14: 299–302, 1986
Olczak SA, Greenwood RH, Hales CN. Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetics. Hormone Metabolic Research 18: 38–41, 1986
Oli JM, Ikeakor IP. The use of piroxicam in diabetics with arthropathies. Current Therapeutic Research, Clinical Experiments 36: 46–50, 1984
Osei K, Holland G, Falko JM. Indapamide: effects on apoprotein, lipoprotein and glucoregulation in ambulatory diabetic patients. Archives of Internal Medicine 146: 1973–1977, 1986
Ostrander Jr LD, Francis Jr T, Hayner NS, Kjelsberg MO, Epstein FH. The relationship of cardiovascular disease to hyperglycaemia. Annals of Internal Medicine 62: 1188–1198, 1965
Pagano G, Cavalco-Perin P, Cassader M, Bruno A, Ozzello A, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Journal of Clinical Investigation 72: 1814–1820, 1983
Palmieri M, Caffau S, Borgioni L, Chiozza R, Gotti G, et al. The influence of orally given verapamil as an antihypertensive agent on the glucose-induced insulin release in 10 mildly hypertensive patients with impaired glucose tolerance. International Symposium on Calcium Antagonism in Cardiovascular Therapy, Experience with Verapamil, Florence, October, 1980, pp. 141–143, Centro Editoriale Pubblicitario Italiano Roma, 1980
Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. British Medical Journal 294: 1443–1447, 1987
Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. British Medical Journal. 297: 1086–1091, 1988
Passariello N, Giugliano D, Quatraro A, Consoli G, Sgambato S, et al. Glucose tolerance and hormonal responses in heroin addicts: a possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism 32: 1163–1165, 1983
Perley M, Kipnis DM. Effect of glucocorticoids on plasma insulin. New England Journal of Medicine 274: 1237–1241, 1966
Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, et al. The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: a controlled trial. Clinical Endocrinology 12: 575–580, 1980
Peters BH, Samaan NA. Hyperglycaemia with relative hypoinsulinaemia in diphenylhydantoin toxicity. New England Journal of Medicine 281: 91–92, 1969
Phillips G, Safrit H. Alcoholic diabetes: induction of glucose intolerance with alcohol. Journal of the American Medical Association 217: 1513–1519, 1971
Podolsky S, Patavina CG. Hyperosmolar nonketotic diabetic coma: a complication of propranolol therapy. Metabolism 22: 685–693, 1973
Polak JMM, Sullivan SN, Bloom SR, Facer P, Pearse AGE. En-kephalin-like immunoreactivity in the human gastrointestinal tract. Lancet 1: 972–974, 1977
Politi A, Poggio G, Margiotta A. Can amiodarone induce hyperglycaemia and hypertriglyceridaemia? British Medical Journal 288: 285, 1984
Raftos J, Bauer GE, Lewis RG. Clonidine in the treatment of severe hypertension. Medical Journal of Australia 1: 786–793, 1973
Rapoport MI, Hurd HF. Thiazide-induced glucose intolerance treated with potassium. Archives of Internal Medicine 113: 405–408, 1964
Rayfield EJ, George DT, Eichner HL, Hsu TH. L-Dopa stimulation of glucagon secretion in man. New England Journal of Medicine 293: 589–591, 1975
Regal H, Lageder H, Irsigler K, Maggi E, Mandelli V, et al. Effect of a single oral dose of acipimox on glucose utilization after intravenous glucose load in obese patients. Drugs Under Experimental and Clinical Research 10: 621–625, 1984
Reid J, MacDougall AI, Andrews MM. Aspirin and diabetes mellitus. British Medical Journal 4: 1071–1074, 1957
Reid RL, Sandler JA, Yen SSC. Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus. Metabolism 33: 197–199, 1984
Reid RL, Yen SSC. Beta-endorphin stimulates the secretion of insulin and glucagon in humans. Journal of Clinical Endocrinology and Metabolism 52: 592–594, 1981
Reilly IAG, FitzGerald GA. Aspirin in cardiovascular disease. Drugs 35: 154–176, 1988
Rett K, Wicklmayr M, Dietze GJ. Hypoglycaemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. Correspondence. New England Journal of Medicine 319: 1609, 1988
Reuter H. A variety of calcium channels. Nature 316: 391, 1985
Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanism for the effects of epinephrine on glucose production and clearance in man. Journal of Clinical Investigation 65: 682–689, 1980
Robinson D, Nilsson C, Leonard R, Horton E. Effects of loop diuretics on carbohydrate metabolism and electrolyte excretion. Journal of Clinical Pharmacology 21: 637–646, 1981
Rojdmark S, Andersson DEH. Influence of verapamil on human glucose tolerance. American Journal of Cardiology 57 (Suppl. D): 39–43, 1986
Röjdmark S, Andersson DEH, Hed R, Sunblad L. Calcium-antagonistic effects on glucose response to glucagon in patients with non-insulin-dependent diabetes mellitus and in normoglycaemic subjects. Hormone and Metabolic Research 13: 664–667, 1981
Rosatti G, Maioli M, Aiello I, Farris A, Agnetti V. Effects of longterm L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. European Neurology 114: 229–239, 1976
Royal College of General Practitioners Oral Contraceptive Study. Mortality among oral contraceptive users. Lancet 2: 727, 1979
Salmela PI, Sotaniemi EA, Pelkowen RD. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Diabetes 29: 788–794, 1980
Samaan NA, Dollery CT, Fraser R. Diabetogenic action of benzothiadiazines. Lancet 2: 1244–1246, 1963
Samarthji LAL, Tolis G, Martin JB, Brown GM, Guyda H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone and thyroid-stimulating hormone in the serum of normal men. Journal of Clinical Endocrinology and Metabolism 41: 827–832, 1975
Sasaki A, Susuki T, Horiuchi N. Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow-up study. Diabetologia 22: 154–157, 1982
Sasaki A, Uehara M, Horiuchi N, Hasagawa K. A long-term follow-up study of Japanese diabetic patients: mortality and causes of death. Diabetologia 25: 309–312, 1983
Seviour PW, Teal TK, Richmond W, Elkeles RS. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention. Diabetic Medicine 5: 166–171, 1988
Shah JH, De Leon-Jones FA, Shickler R, Nasr S, Mayer M, et al. Symptomatic reactive hypoglycaemia during glucose tolerance test in lithium-treated patients. Metabolism 35: 634–639, 1986
Shamoon H, Baylor P, Kambosos D, Charlap S, Plawes S, et al. Influence of oral verapamil on glucoregulatory hormones in man. Journal of Clinical Endocrinology and Metabolism 60: 536–541, 1985
Shanghai Diabetes Research Co-operative Group. Diabetes mellitus survey in Shanghai. Chinese Medical Journal 93: 663–672, 1980
Shopsin B, Stern S, Gershon S. Altered carbohydrate metabolism during treatment with lithium carbonate. Archives of General Psychiatry 24: 566–571, 1972
Sirtori CR, Bohme P, Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. New England Journal of Medicine 287: 729–733, 1972
Skarfors ET, Lithell HO, Selinus I, Åberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? British Medical Journal 298: 1147–1152, 1989
Small M, Forbes CD, MacCuish AC. Metabolic effects of stanozolol in Type II diabetes mellitus. Hormone and Metabolic Research 18: 647–648, 1986
Smith GD, Amos TAS, Mahler R, Peters TJ. Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus. British Medical Journal 294: 465–467, 1987
Smith GD, Peters TJ. The localization in rat liver of alkaline phosphodiesterase to a discrete organelle implicated in ligand internalization. Biochimica et Biophysica Acta 716: 24–30, 1982
Soreth JT, Dubb JW, Allison NL, Alexander F, Boden G, et al. Effect on the endocrine system of a new dopaminergic agent, ibopamine. Clinical Pharmacology and Therapeutics 41: 627–632,1987
Sorkin EM, Heel RC. Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31: 301–336, 1986
Sotaniemi EA, Arranto AJ, Salmela PI, Stengård JH, Pelkonen RO. Hepatic microsomal enzyme activity in patients with noninsulin dependent diabetes mellitus (NIDDM) and its clinical significance. Acta Endocrinologica 105 (Suppl. 262): 125–129, 1984
Sotaniemi EA, Arranto AJ, Sutinen S, Stengård JH, Sutinen S. Treatment of non-insulin-dependent diabetes mellitus with enzyme inducers. Clinical Pharmacology and Therapeutics 33: 826–835, 1983
Sotaniemi EA, Lahtela JT, Stengård J. Enzyme induction and glucose metabolism. In Sotaniemi EA & Pelkonen RO (Eds) pp. 219–230, Taylor and Francis, New York, 1987
Spellacy WN. A review of carbohydrate metabolism and the oral contraceptives. American Journal of Obstetrics and Gynecology 104: 448–460, 1969
Stahl-Bayliss CM, Kaiman CM, Laskin OL. Pentamidine-induced hypoglycaemia in patients with the acquired immune deficiency syndrome. Clinical Pharmacology and Therapeutics 39: 271–275, 1986
Steinbach LH, Randall LO, Gustofson SR. 1,5-benzodiazepines. In Gordon M (Ed.) Psychopharmacological agents, Vol. 1, pp. 198–200, Academic Press, New York, 1964
Stokes III J, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 75 (Suppl. V): 65–73, 1987
Thomas DJ, Brown PM, Stubbs WA. Salbutamol induced diabetic ketoacidosis. British Medical Journal 2: 438, 1977
Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension 7 (Suppl. 11): 152–156, 1985
Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. American Journal of Psychiatry 124: 978–982, 1968
Töterrman K, Groop L, Groop PH, Kala R, Tolppanen EM, et al. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. European Journal of Clinical Pharmacology 26: 13–17, 1984
Trost BN, Weidmann P. Effects of nitrendipine and other calcium antagonists on glucose metabolism in man. Journal of Cardiovascular Pharmacology 6 (Suppl. 7): 986–995, 1984
Van der Velde CD, Gordon MW. Manic-depressive illness, diabetes mellitus, and lithium carbonate. Archives of General Psychiatry 21: 478–485, 1969
Van Woert MH, Mueller PS. Glucose insulin and free fatty acid metabolism in Parkinson’s disease treated with levodopa. Clinical Pharmacology and Therapeutics 12: 360–367, 1971
Vendsborg PB. Lithium treatment and glucose tolerance in melancholic patients. Acta Psychiatrica Scandinavica 59: 306–316, 1979
Vendsborg PB, Prytz S. Glucose tolerance and serum lipids in man after long term lithium administration. Acta Psychiatrica Scandinavica 53: 64–69, 1976
Vendsborg PB, Rafaelsen OJ. Lithium in man: effect on glucose tolerance and serum electrolytes. Acta Psychiatrica Scandinavica 49: 601–610, 1973
Vester JW, Sunder JH, Aarons JH, Danowski TS. Long term monitoring during clofibrate therapy. Clinical Pharmacology and Therapeutics 11: 689–697, 1970
Vierhapper H, Jorg J, Waldhausl W. Effect of acetyl-salicylic acid and of indomethacin or diuresis in man: the role of cyclooxygenase inhibition. Clinical Science 67: 579–583, 1984
Waal-Manning HJ. Metabolic effects of β-adrenoreceptor blockers. Drugs 11 (Suppl. 1): 121–126, 1976
Waitzkin L. A survey for unknown diabetics in a mental hospital. Diabetes 15: 97–104, 1966
Walsh SP, Grant IWB. Corticosteroids in the treatment of chronic asthma. British Medical Journal 2: 796, 1966
Weir GC. Non-insulin-dependent diabetes mellitus: interplay between β-cell inadequacy and insulin resistance. American Journal of Medicine 73: 461–464, 1982
Whitcroft I. Do antihypertensive drugs precipitate diabetes? Correspondence. British Medical Journal 290: 322, 1985
Whitcroft I, Wilkinson N, Rawthorne A, Thomas J, Davies JB. β-Adrenoceptor antagonists impair long-term glucose control in hypertensive diabetics: role of β-adrenoceptor selectivity and lipid solubility. Proceedings of the British Pharmacological Society, 9–11 April. British Journal of Clinical Pharmacology 22: 236P-237P, 1986
WHO Expert Committee on Diabetes Mellitus. 2nd report. WHO Technical Report Series, No. 646, 1980
WHO Study Group on Diabetes Mellitus. Diabetes mellitus. WHO Technical Report Series No. 727, 1985
Wicklmayr M, Dietze G, Guenther B, Boettger I, Mayer L, et al. Improvement of glucose assimilation and protein degradation by bradykinin in maturity onset diabetics and in surgical patients. In Fujii S et al. Kinins 11, Vol. 76, pp. 569–576, Plenum, New York, 1979
Wolff FW, Parmlcy WW, White K, Okun R. Further observations concerning the hyperglycaemic activity of benzothiadiazines. Diabetes 13: 115–121, 1964
Woods KL, Wright AD, Kendall MJ, Black E. Lack of effect of propranolol and metoprolol on glucose tolerance in maturityonset diabetics. British Medical Journal 281: 1321, 1980
Wray R, Sutcliffe SBJ. Propranolol-induced hypoglycaemia and myocardial infarction. Correspondence. British Medical Journal 2: 592, 1972
Wright AD, Barber SQ, Kendall MJ, Poole PH. Beta-adrenoceptor-blocking drugs and blood sugar. British Medical Journal 1: 159–161, 1979
Wynn V. Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism. American Journal of Obstetrics and Gynecology 142: 739–746, 1982
Wynn V, Godsland I, Niththyanan Than R, Adams PW, Melrose J, et al. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1: 1045–1049, 1979
Zavaroni I, Dall’Aglio E, Bonoka S, Alpi O, Passeu M, et al. Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. American Journal of Medicine 83: 609–612, 1987
Zimmett P. Epidemiology of diabetes and its macrovascular manifestations in Pacific populations: the medical effects of social progress. Diabetes Care 2: 144–153, 1979
Zumoff B, Hellman L. Aggravation of diabetic hyperglycaemia by chlordiazepoxide. Journal of the American Medical Association 237: 1960–1961, 1977
Author information
Authors and Affiliations
Additional information
Part I of this article appeared in the previous issue of the Journal.
Rights and permissions
About this article
Cite this article
O’Byrne, S., Feely, J. Effects of Drugs on Glucose Tolerance in Non-Insulin-Dependent Diabetics (Part II). Drugs 40, 203–219 (1990). https://doi.org/10.2165/00003495-199040020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199040020-00003